OTC · Biotechnology

Valneva SE (INRLF) Stock

$2.43 -7.25% OTC: INRLF Healthcare

Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis.

Valuation

MetricValue
Price$2.43
Market Cap$460.84M
P/E Ratio-2.67
P/B Ratio4.86
P/S Ratio2.63
EPS (TTM)$-0.68
52-Week High$6.28
52-Week Low$2.43
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-106.22%
ROA-37.10%
ROCE-38.72%
Gross Margin29.46%
Operating Margin-68.81%
Net Margin-88.30%
Debt/Equity2.73
Current Ratio2.14

Annual Financials (USD)

Metric20212022202320242025
Revenue$348.0M$361.0M$154.0M$170.0M$175.0M
Operating Profit$-61.0M$-113.0M$-82.0M$13.0M$-82.0M
Net Profit$-73.0M$-143.0M$-101.0M$-12.0M$-115.0M
EPS$-0.75$-1.24$-0.73$-0.09$-0.68
Op Margin-17.6%-31.4%-53.4%7.9%-46.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$817.0M$621.0M$460.0M$500.0M$399.0M
Total Liabilities$647.0M$402.0M$332.0M$319.0M$293.0M
Cash$347.0M$289.0M$126.0M$168.0M$110.0M
Borrowings$115.0M$152.0M$209.0M$216.0M$207.0M

Latest News

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 GlobeNewswire · Jul 22, 2026 Declaration voting rights - June 30,2026 GlobeNewswire · Jul 2, 2026 Valneva Announces Successful Outcome of its Annual General Meeting GlobeNewswire · Jun 25, 2026 Valneva Announces Availability of Documentation for its Annual General Meeting GlobeNewswire · Jun 4, 2026 VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026 GlobeNewswire · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$77.0M$-245.0M$-203.0M$-67.0M$-53.0M
Investing Cash Flow$-186.0M$-58.0M$-35.0M$60.0M$-6.0M
Financing Cash Flow$-8.0M$-9.0M$-13.0M$-20.0M$-31.0M
Net Cash Flow$142.0M$-57.0M$-160.0M$42.0M$-59.0M
Free Cash Flow$-16.0M$-275.0M$-217.0M$-84.0M$-57.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-5.95
FCF Yield-16.84%
Quick Ratio1.60
Interest Coverage-2.62
Return 1Y-36.55%
Return 3Y-67.43%
Return 5Y—

Ownership

Insiders Held10.72%
Institutions Held24.56%
Institutions Float Held27.51%
Institutional HolderSharesReport Date
General American Investors Company, Inc.1,152,1802026-03-31
iShares Trust-iShares Core MSCI EAFE ETF926,9732026-06-30
iShares Trust-iShares MSCI EAFE Small-Cap ETF572,0082026-06-30
iShares Trust-iShares Genomics Immunology and Healthcare ETF343,3212026-06-30
SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E165,9162026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Valneva SE

Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also developed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva is advancing VLA15, a Lyme disease vaccine candidate that has successfully completed Phase II clinical trials. Furthermore, VLA1553, a candidate vaccine against the chikungunya virus, is currently undergoing Phase III clinical evaluation. Valneva distributes its products globally, with a market presence spanning the United States, Canada, Germany, Austria, the Nordic region, the United Kingdom, other European countries, and various international territories. The company has established significant strategic collaborations, including a partnership with Pfizer, Inc. to jointly develop and commercialize its Lyme disease vaccine. It also collaborates with Instituto Butantan on the development, manufacturing, and marketing of a single-dose chikungunya vaccine. Founded in 1998, Valneva SE is headquartered in Saint-Herblain, France.

Valneva SE is headquartered in FR.

Valneva SE (INRLF) stock trades at $2.43 with a market capitalization of $460.84M. The stock is valued at a price-to-earnings (P/E) ratio of -2.67, price-to-book of 4.86, price-to-sales of 2.63. Over the past 52 weeks the stock has ranged between $2.43 and $6.28, and currently trades 61.3% below its 52-week high.

On profitability, Valneva SE generates a return on equity (ROE) of -106.22%, return on capital employed of -38.72%, an operating margin of -68.81%, a net profit margin of -88.30%.

Official website: valneva.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides